Please login to the form below

Not currently logged in
Email:
Password:

Stelara gets NICE approval

Janssen-Cilag gets NICE approval for biologic psoriasis treatment

The National Institute for Health and Clinical Excellence (NICE) has approved Janssen-Cilag's Stelara (ustekinumab) for the treatment of moderate to severe plaque psoriasis in adults.

Stelara, a first in class biologic for the treatment of psoriasis – a notoriously difficult-to-treat skin condition – works by targeting interleukin-12 (IL-12) and IL-23. It provides visible and significant improvements in psoriasis severity; in addition, it has the advantage of a convenient dosing regimen for patients – just five injections per year compared to a possible 104 injections with etanercept, a widely prescribed biologic therapy.

In clinical trials, Stelara demonstrated a significant, visible improvement in patient's psoriasis with convenient 12 weekly maintenance dosing. "Two-thirds of patients taking Stelara in placebo-controlled trials saw a significant, visible improvement in their psoriasis in as little as 12 weeks," said Christopher Griffths, Professor of Dermatology at the University of Manchester.

NICE has recommended Stelara as a treatment option for adults with plaque psoriasis for whom biologic therapy is being considered and when the following criteria are both met:

  • The disease is severe, as defined by a total Psoriasis Area Severity Index score of 10 or more and a Dermatology Life Quality Index score of more than 10
  • The psoriasis has not responded to standard systemic therapies, including ciclosporin, methotrexate and PUVA (psoralen and long-wave ultra-violet radiation), or the person is intolerant of or had a contraindication to these treatments.

    Stelara is a new, fully human monoclonal antibody with a novel mechanism of action that targets the p40 subunit of the cytokines IL-12 and IL-23, which are naturally occurring proteins important in regulating immune responses and are thought to be associated with some immune-mediated inflammatory disorders, including plaque psoriasis.

  • 23rd September 2009

    From: Healthcare

    Share

    COVID-19 Updates and Daily News

    Featured jobs

    PMHub

    Add my company
    HAVAS Just::

    HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

    Latest intelligence

    What challenges still face clinical trial recruitment and retention?
    Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
    “Fake News” and Credibility in Medical Publishing
    Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
    Delivering true value: what does it mean for KAM in cancer care?
    Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

    Infographics